SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.540
-0.410 (-10.38%)
Nov 7, 2024, 1:34 PM EST - Market open
SAB Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 1.51 | 2.24 | 23.9 | 60.88 | 55.24 | 3.44 |
| Revenue Growth (YoY) | -63.06% | -90.63% | -60.73% | 10.21% | 1504.91% | - |
| Cost of Revenue | 16.52 | 16.52 | 36.44 | 57.18 | 27.91 | 8.02 |
| Gross Profit | -15 | -14.28 | -12.53 | 3.69 | 27.33 | -4.58 |
| Selling, General & Admin | 26.39 | 23.8 | 16.38 | 17.09 | 6.77 | 4.1 |
| Operating Expenses | 36.77 | 23.8 | 16.38 | 17.09 | 6.77 | 4.1 |
| Operating Income | -51.78 | -38.08 | -28.92 | -13.39 | 20.56 | -8.67 |
| Interest Expense | -0.33 | -0.32 | -0.3 | -0.29 | -0.47 | -0.43 |
| Interest & Investment Income | 1.63 | 0.58 | 0.07 | 0.02 | 0.03 | 0.11 |
| Other Non Operating Income (Expenses) | 4.94 | -4.34 | 10.38 | -4.15 | 0 | 0 |
| EBT Excluding Unusual Items | -45.52 | -42.15 | -18.76 | -17.81 | 20.12 | -8.99 |
| Gain (Loss) on Sale of Assets | -0.04 | -0.04 | 0.02 | - | - | - |
| Other Unusual Items | - | - | 0.03 | 0.67 | - | - |
| Pretax Income | -45.57 | -42.19 | -18.72 | -17.14 | 20.12 | -8.99 |
| Income Tax Expense | - | - | 0.03 | - | - | - |
| Net Income | -45.57 | -42.19 | -18.74 | -17.14 | 20.12 | -8.99 |
| Net Income to Common | -45.57 | -42.19 | -18.74 | -17.14 | 20.12 | -8.99 |
| Shares Outstanding (Basic) | 9 | 6 | 4 | 3 | 3 | 4 |
| Shares Outstanding (Diluted) | 9 | 6 | 4 | 3 | 3 | 4 |
| Shares Change (YoY) | 74.13% | 26.86% | 59.20% | 1.21% | -23.30% | - |
| EPS (Basic) | -5.28 | -7.64 | -4.31 | -6.27 | 7.92 | -2.55 |
| EPS (Diluted) | -5.28 | -7.64 | -4.31 | -6.30 | 7.40 | -2.60 |
| Free Cash Flow | -38.56 | -25.32 | -25.63 | -8.96 | -2.73 | -9.82 |
| Free Cash Flow Per Share | -4.47 | -4.59 | -5.89 | -3.28 | -1.01 | -2.79 |
| Gross Margin | - | - | -52.44% | 6.07% | 49.48% | -133.01% |
| Operating Margin | -3422.67% | -1700.56% | -120.97% | -22.00% | 37.22% | -252.01% |
| Profit Margin | -3012.27% | -1884.50% | -78.40% | -28.16% | 36.42% | -261.09% |
| Free Cash Flow Margin | -2548.80% | -1130.71% | -107.20% | -14.71% | -4.94% | -285.41% |
| EBITDA | -46.91 | -34.42 | -25.75 | -11.9 | 20.94 | -8.48 |
| EBITDA Margin | - | - | -107.71% | -19.56% | 37.91% | -246.28% |
| D&A For EBITDA | 4.86 | 3.65 | 3.17 | 1.49 | 0.38 | 0.2 |
| EBIT | -51.78 | -38.08 | -28.92 | -13.39 | 20.56 | -8.67 |
| EBIT Margin | - | - | -120.97% | -22.00% | 37.22% | -252.01% |
| Revenue as Reported | 1.51 | 2.24 | 23.9 | 60.88 | 55.24 | 3.44 |
Source: S&P Capital IQ. Standard template. Financial Sources.